Company's CEO and CFO Highlights its Cutting-Edge Gene Therapy ProgramsAUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in CEO/CFO Magazine discussing the Company's novel gene therapies for cancer and diabetes.In ...

Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in MesotheliomaAUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-renow ...

Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development ProgramNew Subsidiary to Focus on Developing Novel Gene Therapy for DiabetesAUSTIN, Texas, Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company's diabetes clinical development program and its diabete ...

Presentation to Highlight the Company's Gene Therapies for Cancer and DiabetesAUSTIN, Texas, Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in September 2024.Event: H.C. Wainwright 26th Annual Global Investment ConferenceConference ...

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient OutcomesVideo Highlights Recent Oncology Clinical Development Program UpdatesAUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study update ...

Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3Re-focuses Oncology Clinical Development Program and Advances Work to Establish Biomarkers to Enrich Clinical Trial Patient PopulationsAUSTIN, Texas, Aug. 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announc ...

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitorsAUSTIN, Texas, Aug. 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Singapore Patent Office has granted a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in co ...

肿瘤治疗技术 - 公司正在开展三项Acclaim临床试验,分别针对小细胞肺癌和非小细胞肺癌[132][134][133] - 公司与MD Anderson合作,进一步开展TUSC2基因和其他肿瘤抑制基因的临床前研究,并开发用于预测和评估靶向治疗反应的生物标志物[131] - 公司的Oncoprex递送系统可以递送多种抗癌肿瘤抑制基因,单独或与其他癌症疗法联合使用,以治疗多种类型的癌症[130][129] - 公司的Reqorsa(quaratusugene ozeplasmid)在临床前研究中显示具有多重作用机制,可以破坏癌细胞代谢、干扰细胞信号通路、重建凋亡通路并增强免疫反应[130] - FDA已经授予Reqorsa用于治疗小细胞肺癌和非小细胞肺癌的快速通道和孤儿药资格[132][134] - Acclaim-1试验中有两名患者长期接受Reqorsa和Tagrisso治疗,取得了部分缓解和稳定病情的疗效[134] 糖尿病治疗技术 - 公司的糖尿病技术旨在通过将胰腺中的α细胞转化为功能性β样细胞来治疗1型糖尿病,并通过补充和振兴耗竭的胰岛素分泌β细胞来治疗2型糖尿病[129] - 公司的糖尿病基因疗法产品正在进行临床前研究，计划于2025年上半年向FDA提交IND申请[135] - 公司正在与匹兹堡大学合作开展II型糖尿病非人类灵长类动物模型的研究[135] 财务状况 - 公司预计研发费用将会增加，主要用于推进产品候选药物的临床试验、生产工艺优化和扩大研发项目[146] - 公司实施了一系列成本控制措施，使得2024年上半年研发费用和管理费用同比大幅下降[150,151,153] - 公司2024年上半年净亏损同比下降19%,主要得益于成本控制措施的实施[158] - 公司在截至2024年6月30日的六个月内净亏损1,246.47万美元,较2023年同期减少471.83万美元或27%[159] - 公司自成立以来一直未产生产品销售收入,并在每年都产生净亏损,截至2024年6月30日累计亏损14,615.30万美元[160] - 公司主要通过发行股票融资运营[160] - 2023年12月13日公司与H.C. Wainwright & Co., LLC签订了一项"随时市场"融资协议,可以不时发行股票筹集资金[164] - 截至2024年6月30日公司现金及现金等价物为245.90万美元[165] - 公司预计无法在未来12个月内维持足够的流动性持续经营,存在持续经营能力的重大不确定性[166] - 公司2024年上半年经营活动现金流出1,109.37万美元,较2023年同期减少394.58万美元或26%[168] - 公司2024年上半年筹资活动现金流入681.40万美元,较2023年同期增加273.32万美元[170] 临床试验进展 - 公司决定暂停Acclaim-2试验的新患者入组,以集中资源优先推进其他两项Acclaim试验[133] - 公司已完成Acclaim-1试验的1期剂量递增部分,并确定了2期扩展部分的推荐剂量[134]

Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas, June 27, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company's recent achievements across its clinical development ...

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 202 ...